Abstract Coronavirus disease 2019 (COVID-19) has presented a serious worldwide threat to
public health since its emergence in late 2019. From a safety point of view, drug repurposing …

A recent letter in this journal described an avian influenza virus of wild bird origin that is well
adapted to a mammalian host, posing a potential threat to animal and human health. 1 This …

In practicing evidence-based medicine, physicians use the best evidence currently available
on safety and efficacy in making decisions on treatment choices for their patients. During the …

Background: The COVID-19 pandemic has impacted millions of lives globally. While COVID-
19 did not discriminate against developed or developing nations, it has been a significant …

Fluvoxamine has been proven in studies to improve the immune system by reabsorbing
serotonin and to be beneficial in limiting the spread of covid‐19 (in the early stages of the …

In the last 2 years, different pharmacological agents have been indicated as potential
inhibitors of SARS‐CoV‐2 in vitro. Specifically, drugs termed as functional inhibitors of acid …

Widely available effective drugs to treat coronavirus disease-2019 (COVID-19) are still
limited. Various studies suggested the potential contribution of selective serotonin-reuptake …

Here, we describe the characterization of a radioligand selective for GluN2B‐containing
NMDA receptors, 3‐[3H] 1‐(azetidin‐1‐yl)‐2‐(6‐(4‐fluoro‐3‐methyl‐phenyl) pyrrolo [3, 2‐b] …

With 614 million cumulative cases and over 6.3 million deaths worldwide as of September
30, 2022, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic …

Background Recently, several randomized controlled trials (RCTs) of fluvoxamine have
been successfully conducted for the treatment of patients with coronavirus disease 2019 …